Roche Holding AG (RHHBF)
| Market Cap | 380.15B +34.3% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.68 +30.6% |
| Shares Out | n/a |
| PE Ratio | 25.70 |
| Forward PE | 18.38 |
| Dividend | 12.41 (2.59%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 90 |
| Open | 476.79 |
| Previous Close | 479.43 |
| Day's Range | 476.79 - 480.00 |
| 52-Week Range | 301.27 - 514.08 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 28, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Roche Holding AG Earnings Call Transcript: Q3 2026
YTD sales rose 6% CER, with Pharma growth and launches offsetting LOE, China pricing pressure and FX. Mid-single-digit sales growth and high-single-digit core EPS growth remain the 2026 outlook, supported by pipeline progress.
Roche Holding AG Earnings release: Q3 2026
Roche Holding AG released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Roche Holding AG Slides: Q3 2026
Roche Holding AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Roche reports 9M group sales CHF 46.5B vs. CHF 45.9B last year
In the first nine months of 2026, Roche (RHHBY) sales were +6% at CER, +1% when reported in CHF, to CHF 46.5B due to strong demand for pharmaceutical products and…
Roche confirms FY26 outlook
Roche (RHHBY) expects an increase in Group sales in the mid single digit range for 2026. Core earnings per share are targeted to develop in the high single digit range.
Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units
Roche reiterated its full-year guidance and said it is prepared to launch its giredestrant breast-cancer pill later this year.
Roche third quarter sales slightly beat expectations with growth across divisions
Swiss drugmaker Roche beat third-quarter sales expectations on Thursday, supported by steady demand for key medicines such as Ocrevus to buy time as it looks abroad to restock a pipeline facing loom...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2...
Genentech announces new Phase III data for fenebrutinib
Genentech, a member of the Roche (RHHBY) Group, announced new Phase III data for investigational fenebrutinib in multiple sclerosis, demonstrating reduced markers of chronic brain inflammation as well...
Roche says experimental MS pill cuts relapses by 55% in late-stage trials
Roche said on Wednesday late-stage trial data showed its experimental drug fenebrutinib reduced markers of chronic brain inflammation and delivered broader disease control than comparator treatments...
Roche intends to make comeback with oncology pill treatment, Bloomberg says
Roche (RHHBY) Holding intends to make a comeback with giredestrant, an experimental pill developed in-house meant to prevent breast cancer from growing or returning without the side effects of older…
Roche upgraded to Outperform from Underperform at Oddo BHF
Oddo BHF analyst Florent Cespedes double upgraded Roche (RHHBY) to Outperform from Underperform with a price target of CHF 440, up from CHF 300. The firm cites the company’s diversified…
Hansoh Pharmaceutical enters collaboration, license agreement with Roche
Hansoh Pharmaceutical Group (HNSPF) announces that it has entered into a strategic collaboration and license agreement with Roche (RHHBY). This agreement marks the second collaboration between the two...
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion
The Swiss drugmaker will assume responsibility for outside China, Hong Kong, Macau and Taiwan after the completion of early-stage clinical trials.
Roche to unveil lung, breast cancer data at ESMO 2026
Roche said on Monday it will present new late-stage trial results at the ESMO 2026 cancer meeting in Madrid, including data showing its lung cancer drug divarasib worked better than current KRA...
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech to present new data at ESMO across oncology portfolio including positive Phase III Krascendo 1 data in lung cancer.
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical...
Genentech announces FDA approval of Enspryng for the treatment of TED
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Enspryng for the treatment of adults with thyroid eye disease, or TED, providing patients with the first and…
FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has appro...
FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Basel, 16 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab) for the treatment of adults with thyr...
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Swiss drugmaker Roche entered a licensing agreement worth up to $1.16 billion with Rona Therapeutics for its investigational obesity drug candidate, the Chinese biotech firm said on Tuesday.
Roche’s Genentech announces new one-year data from Phase III Meerkat, Sandcat
Genentech, a member of the Roche (RHHBY) Group, announced new one-year data from the Phase III Meerkat and Sandcat studies evaluating investigational vamikibart compared with a sham procedure that mim...
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT s...
Genentech announces FDA approval of Tecentriq combination
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Tecentriq and Tecentriq Hybreza in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III...
FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has appro...